Obecabtagene Autoleucel (obe-cel)

About Autolus Therapeutics

Autolus Therapeutics is a UK-based, publicly traded company focused on building a fully integrated, next-generation CAR T-cell therapy company. Its mission is to deliver life-changing benefits to patients through advanced autologous T-cell therapies. The company's lead program, obe-cel, is in pivotal development for relapsed/refractory adult ALL and is being explored in additional hematological and solid tumor indications, alongside a preclinical pipeline for autoimmune diseases. Autolus employs its proprietary cell programming, manufacturing, and viral vector technologies to develop precise and controlled therapies.

About Autolus Therapeutics

Autolus Therapeutics is a UK-based, publicly traded company focused on building a fully integrated, next-generation CAR T-cell therapy company. Its mission is to deliver life-changing benefits to patients through advanced autologous T-cell therapies. The company's lead program, obe-cel, is in pivotal development for relapsed/refractory adult ALL and is being explored in additional hematological and solid tumor indications, alongside a preclinical pipeline for autoimmune diseases. Autolus employs its proprietary cell programming, manufacturing, and viral vector technologies to develop precise and controlled therapies.

About Autolus Therapeutics

Autolus Therapeutics is a UK-based, publicly traded company focused on building a fully integrated, next-generation CAR T-cell therapy company. Its mission is to deliver life-changing benefits to patients through advanced autologous T-cell therapies. The company's lead program, obe-cel, is in pivotal development for relapsed/refractory adult ALL and is being explored in additional hematological and solid tumor indications, alongside a preclinical pipeline for autoimmune diseases. Autolus employs its proprietary cell programming, manufacturing, and viral vector technologies to develop precise and controlled therapies.

Therapeutic Areas